2-(1,3-dihydroisoindol-2-yl)-3,6-dimethyl-8-[1-[2-(2H-tetrazol-5-yl)anilino]ethyl]quinazolin-4-one
C27H26N8O — CID 169212687
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-(1,3-dihydroisoindol-2-yl)-3,6-dimethyl-8-[1-[2-(2H-tetrazol-5-yl)anilino]ethyl]quinazolin-4-one
2-(1,3-dihydroisoindol-2-yl)-3,6-dimethyl-8-[1-[2-(2H-tetrazol-5-yl)anilino]ethyl]quinazolin-4-one (PubChem CID 169212687) has the molecular formula C27H26N8O and a molecular weight of 478.56 g/mol. Its IUPAC name is 2-(1,3-dihydroisoindol-2-yl)-3,6-dimethyl-8-[1-[2-(2H-tetrazol-5-yl)anilino]ethyl]quinazolin-4-one.
Molecular Properties
| Compound Name | 2-(1,3-dihydroisoindol-2-yl)-3,6-dimethyl-8-[1-[2-(2H-tetrazol-5-yl)anilino]ethyl]quinazolin-4-one |
|---|---|
| PubChem CID | 169212687 |
| Molecular Formula | C27H26N8O |
| Molecular Weight | 478.56 g/mol |
| Exact Mass | 478.22 |
| IUPAC Name | 2-(1,3-dihydroisoindol-2-yl)-3,6-dimethyl-8-[1-[2-(2H-tetrazol-5-yl)anilino]ethyl]quinazolin-4-one |
| SMILES | Cc1cc(C(C)Nc2ccccc2-c2nn[nH]n2)c2nc(N3Cc4ccccc4C3)n(C)c(=O)c2c1 |
| InChI | InChI=1S/C27H26N8O/c1-16-12-21(17(2)28-23-11-7-6-10-20(23)25-30-32-33-31-25)24-22(13-16)26(36)34(3)27(29-24)35-14-18-8-4-5-9-19(18)15-35/h4-13,17,28H,14-15H2,1-3H3,(H,30,31,32,33) |
| InChIKey | VMPOXRCYXHWAKH-UHFFFAOYSA-N |
| XLogP | 4.12 |
| TPSA | 104.62 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 478.56 |
| LogP ≤ 5 | 4.12 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 169212687 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.